1
News
Semiconductor Strategies Shine, Gold Lags: A Look At Winning and Losing Investment Strategies
Shauvik Haldar
|
Growth strategies, esepcially those focused on semiconductors continued their dominance over the last...
The company reported earnings of $1.835 billion, or $1.79 per share, up from $55.4 million, or 6 cents per share, last year. Analysts expected to see EPS of 7 cents.
Revenue
Revenue increased to $6.85 billion from $6.60 billion last year. Analysts expected to see revenue of $6.80 billion.
Outlook
Looking ahead, RAD expects to see FY2016 EPS between 19 cents and 27 cents.
Like other drug companies, Rite Aid is expanding its pharmacy and wellness business to boost sales. During the quarter, prescription sales grew 3.5%; this business segment accounted for 68.1% of total sales.
| Symbol | Mutual Fund | Stake |
|---|---|---|
| RPMGX | T. Rowe Price Mid-Cap Growth | 2.80% |
| PRHSX | T. Rowe Price Health Sciences | 2.31% |
| NAESX | Vanguard Small Cap Index | 1.81% |
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.
Receive email updates about best performers, news, CE accredited webcasts and more.
News
Shauvik Haldar
|
Growth strategies, esepcially those focused on semiconductors continued their dominance over the last...
Aaron Levitt
|
With bond prices low and yields high, fixed income investments could be very...
Aaron Levitt
|
Fund flows into active ETFs underscore how popular the vehicle is for investors...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
The company reported earnings of $1.835 billion, or $1.79 per share, up from $55.4 million, or 6 cents per share, last year. Analysts expected to see EPS of 7 cents.
Revenue
Revenue increased to $6.85 billion from $6.60 billion last year. Analysts expected to see revenue of $6.80 billion.
Outlook
Looking ahead, RAD expects to see FY2016 EPS between 19 cents and 27 cents.
Like other drug companies, Rite Aid is expanding its pharmacy and wellness business to boost sales. During the quarter, prescription sales grew 3.5%; this business segment accounted for 68.1% of total sales.
| Symbol | Mutual Fund | Stake |
|---|---|---|
| RPMGX | T. Rowe Price Mid-Cap Growth | 2.80% |
| PRHSX | T. Rowe Price Health Sciences | 2.31% |
| NAESX | Vanguard Small Cap Index | 1.81% |
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.
Receive email updates about best performers, news, CE accredited webcasts and more.
News
Shauvik Haldar
|
Growth strategies, esepcially those focused on semiconductors continued their dominance over the last...
Aaron Levitt
|
With bond prices low and yields high, fixed income investments could be very...
Aaron Levitt
|
Fund flows into active ETFs underscore how popular the vehicle is for investors...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Receive email updates about best performers, news, CE accredited webcasts and more.
Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.